Lilly is preparing to file data for its experimental breast cancer drug after it was found to reduce disease progression in a late-stage trial. Lilly reported interim data from Phase III Monarch 3 study showed that the addition of abemaciclib to treatment with an aromatase inhibitor in patients with HR+, HER2- advanced breast cancer significantly
Eli Lilly has announced that it will offer its insulin medication, at a 40% discount for eligible patients when purchased through the Blink Health app or website. Patients most likely to save on their purchase of insulin are those with no insurance or are in the deductible phase of their high-deductible insurance plans.
Lilly has recently announced their goal to expand global access to healthcare for 30 million people in resource-limited locations by 2030. The scheme, known as Lilly 30×30, is a new five-year, $90 million investment in the Lilly Global Health Partnership, to improve access to treatment for diabetes, cancer and tuberculosis. One half of the $90
Lilly is hoping to launch 20 new molecular entities in the 2014 to 2023 timeframe, backed up by two new indications or line extensions each year, throughout its core therapeutic categories of diabetes, immunology, oncology, neurodegeneration and pain.
In an unusual move, Eli Lilly has changed the endpoint of an ongoing Phase III trial that assess its experimental beta amyloid antibody solanezumab in patients with Alzheimer’s disease.
Eli Lilly and Boehringer Ingelheim’s Jardiance has become the first diabetes drug to show a significant reduction in cardiovascular deaths in a dedicated outcomes study. According to data* from the 7,000-plus patient trial EMPA-REG OUTCOME, Jardiance (empagliflozin) cut the risk of cardiovascular death by 38% when added to standard of care in type II diabetics
Results from three late-stage clinical trials have demonstrated that Eli Lilly’s diabetes drug, Peglispro, is more effective at reducing blood sugar in patients with type II diabetes than Sanofi’s Lantus. Yesterday, Eli Lilly confirmed that they are expecting to file for regulatory approval by the first quarter of 2015, after the Phase III clinical studies
Eli Lilly has announced the results of their head-to-head clinical study which demonstrates that their investigational GLP-1 glucagon-like peptide 1 receptor agonist, dulaglutide, is just as effective as Novo Nordisk’s Victoza, the market-leader in the area. The pharmaceutical company revealed the positive top-line results of the sixth clinical trial in their AWARD programme, whereby once-weekly
Eli Lilly has announced an 11% fall in their third-quarter sales to $5.4 billion, as generic competition to Zyprexa continued to hurt sales. Net income (GAAP) for the period increased by 7% to $1.3 billion, as the drop in sales was counteracted by a $1.4 billion payment from Bristol-Myers Squibb, as a result of the
Patients in the UK with type II diabetes now have access to a new alternative for managing their blood glucose levels with the launch of Boehringer Ingelheim/Eli Lilly’s new combination drug, Jentadueto, being launched in the UK this week. Jentadueto combines two antiglycaemic therapies – the veteran drug metformin with the dipeptidyl peptidase (DPP)-IV inhibitor